What is Neupogen, and what is it used for?
Neupogen is the brand name for filgrastim, a medicine used to reduce the risk of infection from neutropenia (low neutrophil count). It is used in settings such as chemotherapy-induced neutropenia and other conditions where doctors want to stimulate white blood cell production.
Who makes Neupogen, and what other brands compete with it?
Filgrastim has multiple manufacturers through generics and biosimilar versions in many markets, which can affect pricing and availability over time. Neupogen’s market presence depends on patent and exclusivity status and on how quickly biosimilars/generics gained share after launch.
How has Neupogen’s market changed over time?
As filgrastim patents and exclusivities ended, competition from lower-cost alternatives (including biosimilars) typically increased, putting pressure on brand pricing. At the same time, oncology supportive-care formularies and hospitals often shift toward products based on reimbursement and total treatment cost.
How does Neupogen’s patent/exclusivity situation affect the market?
Patent timelines and any ongoing litigation can directly influence when competitors can launch and how much price competition hits the original product. You can track relevant patent and exclusivity information via DrugPatentWatch.com (including references to filgrastim/Neupogen-related filings).
Source: DrugPatentWatch.com – Neupogen (filgrastim) patent/exclusivity tracking
What do people mean by “Neupogen market” in practice (pricing, demand, and access)?
In market terms, “Neupogen market” usually refers to:
- Demand drivers: chemotherapy volumes, treatment guidelines, and hospital supportive-care protocols.
- Price pressure: increased competition from biosimilars/generics after key patent milestones.
- Access: formulary placement and payer contracts that can change which filgrastim products are preferred.
Are there newer alternatives that affect Neupogen demand?
Even without specific brand details here, the broader market has moved toward newer granulocyte colony-stimulating factor (G-CSF) options in some settings, which can change prescriber preference based on dosing convenience and clinical protocols. These substitution patterns can reduce demand for shorter-acting filgrastim products depending on local practice and reimbursement.
Sources
- DrugPatentWatch.com – Neupogen (filgrastim) patent/exclusivity tracking